TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

Daniel H Palmer, Juan W Valle, Yuk Ting Ma, Olusola Faluyi, John P Neoptolemos, Trine Jensen Gjertsen, Berit Iversen, Jon Amund Eriksen, Anne-Sophie Møller, Anne-Kirsti Aksnes, Robert Miller, Svein Dueland, Daniel H Palmer, Juan W Valle, Yuk Ting Ma, Olusola Faluyi, John P Neoptolemos, Trine Jensen Gjertsen, Berit Iversen, Jon Amund Eriksen, Anne-Sophie Møller, Anne-Kirsti Aksnes, Robert Miller, Svein Dueland

Abstract

Background: TG01 is the first cancer immunotherapy targeting KRAS oncogenic mutations. This study assessed the safety and efficacy of TG01/GM-CSF in patients with resected pancreatic adenocarcinoma.

Methods: Patients with stage I or II pancreatic adenocarcinoma who had undergone surgical resection (R0 or R1) received adjuvant gemcitabine with TG01/GM-CSF using two schedules of vaccination. Immune response was defined as a positive delayed-type hypersensitivity (DTH) response and/or positive T-cell proliferation assay.

Results: Thirty-two patients were enrolled between February 2013 and May 2016. Nineteen were treated with the high antigen burden, with four serious adverse reactions considered possibly related to TG01 treatment, including three allergic reactions. On this basis, a further 13 patients received a modified vaccination schedule with reduced antigen burden, with no serious adverse events related to TG01. Ninety-five percent patients in the main cohort and 92% in the modified cohort had a positive immune response. Median overall survival (OS) was 33.1 months, and median disease-free survival (DFS) was 13.9 months for the main cohort. For the modified cohort, the median OS was 34.3 months and median DFS was 19.5 months.

Conclusions: TG01/GM-CSF with gemcitabine was well tolerated, with high levels of immune activation. OS and DFS compare favourably with published data for adjuvant gemcitabine.

Clinical trial registration: This clinical trial was registered at ClinicalTrials.gov (NCT02261714).

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
OS by treatment cohort.
Fig. 2. OS was assessed until the…
Fig. 2. OS was assessed until the last patient had been in the study for 3 years.
The blue arrow indicates that the patient had been censored for DFS, meaning the patient was disease-free at the last CT scan collected in the study. The red arrow indicates that the patient had been censored for OS, meaning the patient was alive at the last contact collected in the study.

References

    1. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004;350:1200–1210. doi: 10.1056/NEJMoa032295.
    1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer a randomized controlled trial. JAMA. 2007;297:267–277. doi: 10.1001/jama.297.3.267.
    1. Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resected pancreatic cancer—how to improve long-term survival. World J. Gastrointest. Oncol. 2016;8:248–257. doi: 10.4251/wjgo.v8.i3.248.
    1. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–1081. doi: 10.1001/jama.2010.1275.
    1. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024. doi: 10.1016/S0140-6736(16)32409-6.
    1. Khorana A, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2017;35:2324–2328. doi: 10.1200/JCO.2017.72.4948.
    1. Conroy P, Hammel P, Hebbar M, Abdelghani B, Wei AC, Raoul JL, et al. FOLFIRINOX OR gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 2018;379:2395–2406. doi: 10.1056/NEJMoa1809775.
    1. Capella G, Cronauer-Mitra, Peinado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-RAS gene in human tumors. Environ. Health Perspect. 1991;93:125–131. doi: 10.1289/ehp.9193125.
    1. Kim J, Reber HA, Dry SM, Elashoff D, Chen SL, Umetani N, et al. Unfavourable prognosis associated with K-ras gene mutation in pancreas cancer surgical margins. Gut. 2006;55:1598–1605. doi: 10.1136/gut.2005.083063.
    1. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, et al. Intradermal ras peptide vaccination with granulocyte-mqacrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer. 2001;92:441–450. doi: 10.1002/ijc.1205.
    1. Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, et al. Long term follow-up of resected pancreatic cancer patients following vaccination against mutant K-RAS. Int. J. Cancer. 2011;128:1120–1128. doi: 10.1002/ijc.25449.
    1. Gjertsen MK, Sæterdal I, Larssen SS, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induces by vaccination with T-helper epitopes. J. Mol. Med. 2003;81:43–50. doi: 10.1007/s00109-002-0390-y.
    1. Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet. 2014;15:829–840. doi: 10.1016/S1470-2045(14)70236-0.
    1. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalation phase I/II study. Br. J. Cancer. 2006;95:1474–1482. doi: 10.1038/sj.bjc.6603437.
    1. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481. doi: 10.1001/jama.2013.279201.
    1. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet. 2016;388:248–257. doi: 10.1016/S0140-6736(16)30583-9.
    1. Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein WO, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resected pancreatic cancer: a multicenter randomized phase III trial. J. Clin. Oncol. 2017;33:3330–3337. doi: 10.1200/JCO.2017.72.6463.
    1. Sinn M, Liersch T, Gellert K, Riess H, Stübs P, Waldschmidt DT, et al. CONKO-006: a randomized double-blinded phase IIb-study of adjuvant therapy with gemcitabine+sofafenib/placebo for patients with R1-resection of pancreatic cancer. Ann. Oncol. 2014;25:v1–v41. doi: 10.1093/annonc/mdu438.18.
    1. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J. Clin. Oncol. 2010;28:4450–4456. doi: 10.1200/JCO.2010.30.3446.
    1. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J. Clin. Oncol. 2014;32:504–512. doi: 10.1200/JCO.2013.50.7657.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj